Inflammation is implicated in the etiology of sporadic
colon cancer (CC), which is one of the leading causes of
cancer-related deaths worldwide. Here, we report that inhibition of the inflammatory receptor CysLT1 through its antagonist,
montelukast, is beneficial in minimizing stemness in CC and thereby minimizing
tumor growth in a mouse xenograft model of human
colon cancer. Upon treatment with
montelukast, colonospheres derived from HT-29 and SW-480 human
colon cancer cells exhibited a significant phenotypic change coupled with the downregulation of
mRNA and
protein expression of cancer stem cell (CSC) markers ALDH1 and DCLK1. Moreover,
montelukast reduced the size of HT-29 cell-derived
tumors in mice. The reduction in
tumor size was associated with decreased levels of ALDH1A1, DCLK1, BCL2
mRNA and macrophage infiltration into the
tumor tissue. Interestingly, this treatment elevated levels of the
tumor suppressor
15-PGDH while reducing COX-2 expression. Our data highlight the association of
CysLT1R with CSCs and demonstrate that inhibition of
CysLT1R could prove beneficial in minimizing CSC-induced
tumor growth. This work advances the notion that targeting CSCs is a promising approach to improve outcomes in those afflicted with
colon cancer.